☰

RentschlerBiopharma

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of RentschlerBiopharma's published strategy and is not endorsed by, or produced in cooperation with, RentschlerBiopharma. Company website

Strategic priorities

RentschlerBiopharma operates across 4 stated priorities, with the most concrete near-term plan anchored on core biologics concentration.

Strategic exit from advanced therapy medicinal products (ATMPs) at Stevenage facility to focus exclusively on cell-culture-based therapeutic protein formats, use a track record where Rentschler contributed to nearly 25% of all FDA-approved biologics in 2023.

Commitment to UN Global Compact and Science Based Targets initiative (SBTi) to align with 1.5C climate goal, targeting waste separation rate of over 65% in Laupheim by 2027 and enforcing Supplier Code of Conduct based on German Supply Chain Due Diligence Act (LkSG).

Execution of largest single investments in company history, including state-of-the-art buffer media station in Laupheim (3,400 square meters) and four new 2,000L single-use bioreactors in Milford, designed for high-level automation and digitalization.

Challenges we see

  • IT Infrastructure Digital

    Legacy IT Infrastructure and Global Scalability

    Historically, Rentschler's growth was hampered by outdated infrastructure that limited network scalability and flexibility. Managing disparate international sites (Laupheim and Milford) through a fragmented network created complexity in ensuring durable operational security and data integrity in a highly regulated environment.

    Vulnerable legacy PLCs and SCADA systems pose a risk of production sabotage or regulatory compliance gaps. Without a modernized network fabric, supporting the hypersegmentation required for advanced cyber resilience remains difficult.

  • Digital Transformation Digital, Labor

    Joining records across systems

    Despite the push for Industry 4.0, a digital maturity gap exists between existing operations and the target "Facility of the Future" state. Manual data collection is identified as cumbersome, leading to broken data chains and data islands where information is not contextualized from sensor to scientist.

    High dependency on manual labor in processes like buffer and media preparation leads to slower production cycles and higher risk of human error. According to industry data, 60% of CDMOs still operate at preliminary digital maturity, which can lead to documentation-related deviations.

  • Compliance Energy, Labor, Digital

    Regulatory Compliance and Supply Chain Transparency

    Rentschler must navigate the German Supply Chain Due Diligence Act (LkSG), requiring strict risk analysis for human rights and environmental standards across its direct supply chain. This includes identifying particularly sensitive areas like child labor, discrimination, and occupational health and safety.

    A minor gap exists in areas where awareness of human rights and environmental issues is not yet fully developed. Without rigorous sustainability assessments, regulatory penalties or loss of contracts from sponsors who prioritize ESG transparency could follow.

  • Workforce Labor, Digital

    Skill Gaps and Cultural Resistance

    The transition to a TechBio model requires a fundamental shift in mindset from isolated digitization to synchronized effort. Internal research indicates that lack of knowledge is a primary barrier for 57% of labs pursuing digital transformation.

    Without dedicated transformation teams that bridge the gap between IT and scientific domains, Rentschler risks executive hesitation and a technology-first approach that does not address cultural complexities.

  • Operations Manufacturing

    Complex Multispecific Antibody Manufacturing

    Rentschler's strategic partnership with Coriolis Pharma addresses the increasing complexity of multispecific antibodies and the demand for a unified interface that reduces tech transfer risks. The complexity of next-generation therapeutic proteins requires advanced process control and simulation capabilities.

    Without digital twin capabilities and advanced process analytics, Rentschler faces timeline slippage and high material waste from failed wet-lab experiments, limiting competitiveness in the complex biologics market.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. High Labor Intensity in Media Preparation

    Current buffer and media preparation processes require manual mixing, solute handling, and rigorous hygiene checks in disconnected areas of the facility, resulting in non-standardized production processes and potential delays.

    Implementation of an automated, digitally integrated buffer media station utilizing high-precision automation and real-time monitoring to reduce manual labor and enable immediate responses to process deviations.

  2. Fragmented Global Site Visibility

    Operating multiple sites (Germany/USA) with separate IT/OT architectures prevents a single source of truth, making it difficult to optimize capacity and standardize quality across the organization.

    Deploying a unified Industrial Data Platform and Extreme Fabric network providing hypersegmentation for security and a central repository for real-time analytics, allowing global leadership to monitor production metrics from any location.

  3. Cost and Time of Failed Wet-Lab Experiments

    Biological process development is traditionally iterative and expensive. Failed experiments in the wet lab lead to timeline slippage and high material waste.

    Adopting Digital Twin simulations for biopharma processes by digitizing process know-how into predictive models, allowing Rentschler to simulate 100% of the bioprocess environment and find optimal conditions before starting a single batch.

  4. Opaque Supply Chain ESG Risks

    The German Supply Chain Act (LkSG) requires granular tracking of supplier ethics, which is difficult with manual paper-based assessment systems.

    AI-driven supply chain risk analysis systems that automate supplier screening using media data, certifications, and audits to ensure continuous compliance and satisfy high sponsor ESG expectations.

  5. Digital Skills Gap and Workforce Readiness

    The transition to TechBio requires fundamental mindset shifts, yet 57% of labs cite lack of knowledge as a primary barrier. Digital hesitancy and paper habits persist among highly skilled scientists.

    Implementing structured digital onboarding programs and UX-driven interface redesigns to build trust and competence, transforming passive users into Digital Operators who maximize ROI from technology investments.

What we'd propose

  • Digital CDMO

    Digital Manufacturing and Automation Implementation

    Accelerating the transition to Industry 4.0 through deployment of automated control platforms, modular bioprocess equipment, and MTP-compliant software for rapid reconfiguration of buffer media systems.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Industrial Data Platform and IT/OT Convergence

    Building ontology-based data platforms with automatic pipelines to harmonize data from diverse devices and sensors across global sites, creating a single source of truth for real-time analytics.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Lab and Smart Connectivity

    Integrating lab equipment and digitizing operations to accelerate the drug development life cycle, eliminating data islands through legacy equipment retrofitting and paperless lab processing.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Supply Chain ESG Compliance Platform

    Building AI-driven supply chain risk analysis systems that automate supplier screening using media data, certifications, and audits to ensure continuous LkSG compliance.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Workforce Transformation Program

    Implementing structured digital onboarding programs, UX-driven interface redesigns, and change management frameworks to bridge the gap between IT and scientific domains.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what RentschlerBiopharma's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
IT/OT Connectivity 45 → 95
Significant progress via Extreme Fabric deployment, but legacy PLCs in older Laupheim sections remain siloed
Process Automation 50 → 90
New buffer station (operational 2028) will transition from manual to high-precision automation
Data Integrity and Compliance 65 → 100
Currently reliant on AI-based supply chain screenings and manual audits; target requires 100% digital source-to-scientist chains
Asset Scalability 40 → 85
Legacy network was growth bottleneck; target requires hypersegmentation to support new 2,000L lines in Milford and Laupheim
Digital Twin and Simulation 20 → 80
CDMO sector average shows low adoption; Rentschler needs this to optimize multispecific antibody complexity
Staff Digital Skills 35 → 90
57% knowledge gap cited in industry research; target requires internal upskilling programs and transformation leadership

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with RentschlerBiopharma, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].